Camp4 Therapeutics CORP (CAMP) — SEC Filings

Overview

Camp4 Therapeutics CORP (CAMP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 23, 2026: Camp4 Therapeutics Corp filed an Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The filing includes the complete submission text file and the ARS form itself, with the company's mailing and business address located at One Kendall Square, Cambridge

Sentiment Summary

Across 25 filings, the sentiment breakdown is: 1 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Camp4 Therapeutics CORP is neutral.

Filing Type Overview

Camp4 Therapeutics CORP (CAMP) has filed 1 ARS, 1 DEFA14A, 12 8-K, 4 10-Q, 1 DEF 14A, 1 10-K, 2 SC 13D, 2 S-1/A, 1 S-1 with the SEC between Sep 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (25)

• Camp4 Therapeutics Files Annual Report — ARS · Apr 23, 2026 Risk: low
  Camp4 Therapeutics Corp filed an Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The filing includes the com
• Camp4 Therapeutics Files 2026 Proxy Materials — DEFA14A · Apr 23, 2026 Risk: low
  Camp4 Therapeutics Corp filed a Definitive Additional Materials (DEFA14A) on April 23, 2026, related to its 2026 annual meeting. The filing includes graphic mat
• Camp4 Therapeutics Files 8-K on Officer/Director Changes — 8-K · Mar 24, 2026
  Camp4 Therapeutics Corp filed an 8-K on March 24, 2026, reporting an event that occurred on March 18, 2026, under Item 5.02, which typically covers changes in d
• Camp4 Therapeutics Corp. Enters and Terminates Agreements — 8-K · Dec 23, 2025 Risk: medium
  On December 22, 2025, Camp4 Therapeutics Corp. entered into a material definitive agreement and terminated a material definitive agreement. The filing does not
• 8-K Filing — 8-K · Dec 18, 2025
• Camp4 Therapeutics Corp. Files 8-K for Material Agreement — 8-K · Dec 18, 2025 Risk: medium
  On December 18, 2025, Camp4 Therapeutics Corp. entered into a material definitive agreement. The filing also includes financial statements and exhibits related
• Camp4's Q3 Loss Widens to $15.1M Despite New Collaboration Revenue — 10-Q · Nov 6, 2025 Risk: high
  Camp4 Therapeutics Corp reported a net loss of $15.099 million for the three months ended September 30, 2025, an increase from $13.484 million in the same perio
• Camp4 Therapeutics Files 8-K — 8-K · Oct 1, 2025 Risk: low
  On October 1, 2025, Camp4 Therapeutics Corp. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update r
• Camp4 Therapeutics Files 8-K: Material Agreement, Equity Sales — 8-K · Sep 10, 2025 Risk: medium
  On September 9, 2025, Camp4 Therapeutics Corp. entered into a material definitive agreement, details of which are not fully disclosed in this filing. The compan
• Camp4's Losses Persist Amid Rising R&D, Cash Drains — 10-Q · Aug 14, 2025 Risk: high
  Camp4 Therapeutics Corp (CAMP) reported a net loss of $12.587 million for the three months ended June 30, 2025, a slight increase from $12.576 million in the sa
• Camp4 Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025 Risk: low
  Camp4 Therapeutics Corporation filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders on June 11, 2025. The filing details
• Camp4 Therapeutics Files 8-K — 8-K · May 16, 2025 Risk: low
  Camp4 Therapeutics Corp. filed an 8-K on May 16, 2025, to report current information. The filing does not disclose specific material events, financial statement
• Camp4 Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Camp4 Therapeutics Corp filed a 10-Q for the period ending March 31, 2025. The company, located at One Kendall Square in Cambridge, MA, is in the pharmaceutical
• Camp4 Therapeutics Files Proxy Statement for 2025 Meeting — DEF 14A · Apr 30, 2025 Risk: low
  Camp4 Therapeutics Corp. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 11, 2025. The filing covers the fiscal year endi
• 10-K Filing — 10-K · Mar 27, 2025
• Camp4 Therapeutics Corp. Announces CSO Departure, Director Changes — 8-K · Mar 18, 2025 Risk: medium
  Camp4 Therapeutics Corp. announced on March 12, 2025, the departure of Dr. Jonathan Fleming from his role as Chief Scientific Officer. The company also reported
• 8-K Filing — 8-K · Jan 7, 2025
• Camp4 Therapeutics Files 8-K on Financials — 8-K · Nov 21, 2024 Risk: low
  Camp4 Therapeutics Corp. filed an 8-K on November 21, 2024, reporting on its results of operations and financial condition. The filing provides information rega
• Camp4 Therapeutics Q3 2024 Update — 10-Q · Nov 21, 2024 Risk: medium
  Camp4 Therapeutics Corp. reported its financial results for the period ending September 30, 2024. The company's financial statements indicate a fiscal year end
• Polaris Management Files 13D for Camp4 Therapeutics — SC 13D · Oct 22, 2024 Risk: medium
  On October 22, 2024, Polaris Management Co. VII, L.L.C. and associated individuals filed a Schedule 13D for Camp4 Therapeutics Corp. This filing indicates a cha
• Enavate Sciences Acquires 10% Stake in Camp4 Therapeutics — SC 13D · Oct 22, 2024 Risk: medium
  On October 15, 2024, Enavate Sciences, through Enavate Sciences GP, LLC, filed a Schedule 13D indicating it acquired 10,000,000 shares of Camp4 Therapeutics Cor
• Camp4 Therapeutics Files 8-K — 8-K · Oct 15, 2024 Risk: low
  Camp4 Therapeutics Corporation filed an 8-K on October 15, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The c
• Camp4 Therapeutics Files S-1/A for IPO — S-1/A · Oct 7, 2024 Risk: medium
  Camp4 Therapeutics Corp. filed an S-1/A amendment on October 7, 2024, for its initial public offering. The company, located at One Kendall Square in Cambridge,
• Camp4 Therapeutics Files S-1/A Amendment — S-1/A · Sep 26, 2024 Risk: medium
  Camp4 Therapeutics Corp. filed an S-1/A amendment on September 26, 2024, for its initial public offering. The company, located at One Kendall Square in Cambridg
• Camp4 Therapeutics Files S-1 for Public Offering — S-1 · Sep 20, 2024 Risk: medium
  Camp4 Therapeutics Corp. filed an S-1 registration statement on September 20, 2024, to offer its securities. The company, incorporated in Delaware, is based in

Risk Profile

Risk Assessment: Of CAMP's 21 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Camp4 Therapeutics CORP's most recent 10-Q filing (Nov 6, 2025):

• Revenue: $795K
• Net Income: $ -15.099M
• EPS: $ -0.55
• Debt-to-Equity: N/A
• Cash Position: $75.255M
• Operating Margin: N/A
• Total Assets: $86.395M
• Total Debt: $27.728M

Key Executives

• Dr. Jonathan Fleming
• AMIR NASHAT
• AMY SCHULMAN
• BRIAN CHEE
• Lauren Crockett
• James P. Boylan
• Josh Mandel-Brehm

Industry Context

Camp4 Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and reliance on strategic partnerships for funding and market access. Companies like Camp4 often face challenges in translating scientific innovation into commercially viable products.

Top Tags

sec-filing (7) · pharmaceuticals (3) · ipo (3) · biotech (3) · annual-meeting (2) · corporate-governance (2) · material-agreement (2) · Biotechnology (2) · Net Loss (2) · Cash Burn (2)

Key Numbers

• SEC File Number: 001-42365 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 81-1152476 — Company's tax identification number.
• Net Loss (Q3 2025): $15.099M — Increased from $13.484M in Q3 2024
• Net Loss (9 months 2025): $40.119M — Increased from $38.512M in 9 months 2024
• Research & Collaboration Revenue (Q3 2025): $795K — Significant increase from $0 in Q3 2024
• Research & Collaboration Revenue (9 months 2025): $3.150M — Significant increase from $0 in 9 months 2024
• Cash & Cash Equivalents (Sept 30, 2025): $75.255M — Increased from $64.039M at Dec 31, 2024, providing liquidity
• Proceeds from Equity Issuance: $32.562M — Key driver of increased cash, but also indicates dilution
• Derivative Tranche & Other Liabilities: $16.732M — Significant increase from $2K, representing new financial obligations
• Change in Fair Value of Derivative Tranche Liability: $1.800M — Negative impact on other income/expense for Q3 2025
• Common Stock Shares Outstanding: 46,881,134 — As of November 3, 2025, reflecting significant increase from 20,161,072 at Dec 31, 2024
• Cash and Cash Equivalents: $39.052M — Decreased from $64.039M at Dec 31, 2024, indicating significant cash burn.
• Accumulated Deficit: $236.8M — Increased from $211.753M at Dec 31, 2024, reflecting ongoing losses.
• Net Loss (6 months): $25.020M — Consistent with $25.028M in prior year, showing continued unprofitability.
• Net Cash Used in Operations (6 months): $24.629M — Slightly higher than $24.581M in prior year, indicating persistent operational cash drain.

Frequently Asked Questions